Bacterial Infections
Supporting Assets
Table 1 | Table 2 | Table 3 | Table 4 | Table 5 | Table 6
Table 1. Treatment of Bartonella Infection in Patients With HIV
Indication | First-Choice Treatment | Alternative Options |
Bacillary angiomatosis, cat scratch disease, peliosis hepatitis, bacteremia, and osteomyelitis |
Duration: ≥ 3 mos |
Duration: ≥ 3 mos |
CNS infections and severe infections |
Duration: ≥ 3 mos |
|
Confirmed Bartonella endocarditis* |
Duration: ≥ 3 mos | |
Other severe infections (multifocal disease or with clinical decompensation) |
Duration: ≥ 3 mos |
|
Long-term suppression for patients with relapse or reinfection after treatment completion |
|
|
CNS, central nervous system; IV, intravenous; PO, orally; QD, daily;
*Rifampin is a potent hepatic enzyme inducer and may lead to significant interaction with many drugs, including antiretroviral agents, which may require dose adjustments. Consult Table 5 in the “Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents.”[CDC OI]
†This regimen seen as second line because of potential gentamicin nephrotoxicity as glomerulonephritis frequently complicates Bartonella endocarditis.
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content